Wegovy and pancreatitis: warning signs, how rare it is and what the MHRA says

Acute pancreatitis is the serious Wegovy side effect the leaflet tells you to act on immediately. It is uncommon, affecting up to 1 in 100 people, but it can be life-threatening, and in January 2026 the UK regulator strengthened the warning across every GLP-1 medicine after rare reports of necrotising and fatal cases. This guide explains what the pancreas does, how to tell pancreatitis pain from ordinary Wegovy stomach ache, exactly what the leaflet says to do, and what happens afterwards.

Acute pancreatitis: uncommonMHRA warning strengthened January 2026Checked 20 October 2026Author: Nick Johnson

Stop using Wegovy and seek urgent medical help if you have severe, persistent pain in the stomach area, with or without nausea and vomiting. It may spread through to your back. Call NHS 111 now, or go to A&E or call 999 if you are acutely very unwell.

Key facts

Acute pancreatitis is listed as an uncommon serious side effect of Wegovy: up to 1 in 100 people.
Across the semaglutide weight management trials, confirmed acute pancreatitis was reported in roughly 0.2% of people on the medicine and 0.1% on placebo, so the absolute risk is low but not zero.
The warning sign is severe, persistent pain in the stomach area that may spread to the back, with or without being sick. Ordinary Wegovy stomach discomfort is milder, comes and goes, and tracks with meals and dose steps.
The MHRA Drug Safety Update of January 2026 strengthened the warning for all GLP-1 and GLP-1/GIP medicines, citing rare reports of necrotising and fatal pancreatitis.
If pancreatitis is confirmed, the medicine should not be restarted.
A raised pancreatic enzyme level on a blood test (uncommon) is not the same as pancreatitis and does not on its own mean stopping.

What pancreatitis is

The pancreas sits behind the stomach and makes digestive enzymes and hormones including insulin. Acute pancreatitis is sudden inflammation of the gland, in which those enzymes start to act on the pancreas itself. Most cases in the UK are caused by gallstones or alcohol; medicines are a much less common cause. Mild cases settle in hospital with fluids and pain relief over a few days. Severe cases, where tissue dies (necrotising pancreatitis), can involve organ failure and are the reason the regulator treats even rare reports seriously.

GLP-1 medicines have carried a pancreatitis warning since they were first licensed because the pancreas has GLP-1 receptors and because cases were reported in trials and after marketing. Large trials and registry studies have not shown a big excess, which is why the leaflet band is uncommon rather than common, but the seriousness of the condition means the instruction is unambiguous: stop and get help.

Telling pancreatitis pain from ordinary Wegovy stomach ache

Ordinary Wegovy digestive discomfort	Possible pancreatitis
Mild to moderate, often described as bloating, fullness, cramping or indigestion	Severe, described as the worst stomach pain you have had
Comes and goes; worse after eating, better after a bowel movement or with time	Persistent; does not ease with position, wind, bowel movement or over the counter painkillers
Clusters in the days after a dose step and fades	Can start at any point in treatment, including months in
Usually across the belly or lower down	Typically upper central abdomen, often boring through to the back; leaning forward may ease it slightly
Nausea common, vomiting sometimes	Often with nausea and repeated vomiting, sometimes fever and a fast pulse

This table is a guide to which route to take, not a diagnosis. If you are unsure whether pain is severe enough, treat it as severe: the cost of an unnecessary NHS 111 call is small, the cost of a missed pancreatitis is not.

What the MHRA changed in January 2026

The Drug Safety Update strengthened warnings on acute pancreatitis for all GLP-1 receptor agonists and dual GLP-1/GIP agonists, including semaglutide. It drew on Yellow Card and international reports that included necrotising and, in a small number of cases, fatal pancreatitis. The practical advice to patients did not change in substance but was made more prominent: recognise the symptoms, stop the medicine, seek urgent help, and do not restart if pancreatitis is confirmed. Prescribers were reminded to ask about previous pancreatitis before starting treatment and to counsel patients on the warning signs.

Wegovy also carries the black triangle for additional monitoring, which means the MHRA specifically wants patients and carers to report suspected side effects through the Yellow Card scheme. Reports are what allowed the signal to be assessed.

Who is at higher risk

Previous pancreatitis. The leaflet tells you to talk to your doctor before using Wegovy if you have ever had it. Many UK prescribers will not start treatment after a previous episode.
Gallstones. Gallstones are the leading cause of pancreatitis generally and are themselves a common Wegovy side effect. See the gallstones guide.
Heavy alcohol use. Alcohol is the other leading cause. See the alcohol guide.
Very high triglycerides and some other medicines. Tell your prescriber your full history at the consultation.

What happens if it is pancreatitis

Diagnosis is by blood tests for pancreatic enzymes (lipase and amylase) and usually a scan. Treatment is in hospital with intravenous fluids, pain relief and monitoring; most people are home within a week. The leaflet's instruction is that Wegovy should not be restarted after confirmed pancreatitis. Other weight loss approaches, including non-GLP-1 medicines, remain possible and are a conversation for your prescriber.

If the blood tests are normal and the pain has another cause, restarting is a prescriber decision. Do not restart on your own after an emergency assessment. Our restarting guide covers what prescribers consider.

Frequently asked questions

How common is pancreatitis on Wegovy?

The leaflet lists it as uncommon: up to 1 in 100 people. Trial data put confirmed cases at roughly 0.2% on semaglutide against 0.1% on placebo. It is rare, but serious enough that the instruction is to stop and get help immediately if symptoms appear.

What does Wegovy pancreatitis pain feel like?

Severe, persistent pain in the upper stomach area that may spread to the back, often with nausea and vomiting, sometimes fever. It does not ease with wind, a bowel movement or ordinary painkillers. Mild cramping that comes and goes after meals is not the same thing.

Can I take Wegovy again after pancreatitis?

The leaflet says the medicine should not be restarted if pancreatitis is confirmed. If the diagnosis turns out to be something else, restarting is a prescriber decision.

My blood test showed raised lipase. Is that pancreatitis?

Not on its own. A rise in pancreatic enzymes is listed separately in the leaflet as an uncommon finding, and it can occur without pancreatitis. Your doctor will interpret it alongside symptoms and, if needed, a scan.

Should I stop Wegovy if I get any stomach pain?

No. Mild digestive discomfort is very common and expected, especially after dose steps. The stop instruction is for severe, persistent pain. If you are unsure whether pain is severe, call NHS 111 and let them decide.

Sources and about this guide

Written by Nick Johnson, founder of Medstack Ltd and Independent Prescription Pricing Analyst. Checked 20 October 2026 against the June 2026 leaflet and the January 2026 MHRA update. Next review 5 December 2026. iGovy is an independent price comparison site. It does not sell, prescribe or dispense medicines, and this page is general information, not medical advice. No clinician has reviewed it yet. A named reviewer will be added when appointed.

How this guide was checked: the warning wording is taken verbatim in substance from section 4 of the Wegovy FlexTouch patient leaflet revised June 2026 and from the MHRA Drug Safety Update of January 2026. Trial incidence figures are from section 4.4 of the Summary of Product Characteristics on the eMC, never from pharmacy marketing. NHS pages are used for the description of the condition itself. The page is re-checked whenever the eMC record changes or the MHRA issues a further Drug Safety Update, and at least every three months.

Funding and independence: iGovy earns referral commission when readers use pharmacy discount codes on its price pages. No pharmacy or manufacturer paid for, saw or influenced this guide, and health content is not affected by commercial arrangements. Full policy on the editorial policy page. Corrections via the contact page.